3 days popular7 days popular1 month popular3 months popular

Employers can play a role in cancer prevention and treatment

Employers can have a significant role in improving efforts to prevent and treat diseases such as by introducing and supporting health promotion programs in the workplace. Together, companies can influence health care policies and reimbursement and industry practices to support the fight against . Johnson & Johnson’s active role in implementing the CEO Gold Standard program is described in an article in , a peer-reviewed journal from , Inc., publishers. The article is available on the Population Health Management website.

Rachel Henke, PhD and coauthors representing (Cambridge, MA and Washington, DC), Emory University (Atlanta, GA), and Johnson & Johnson (Southwest Ranches, FL, Mansfield, MA, and New Brunswick, NJ), focus on how J&J has incorporated the industry-leading standards developed by the CEO Roundtable on Cancer into its existing Live for Life worksite health promotion program.

In the article “Employers’ Role in – Developing Success Metrics for Use by the CEO Roundtable on Cancer,” the authors describe the “5 Pillars” of the CEO Cancer Gold Standard program, the framework J&J created to monitor the use and effectiveness of the enhancement efforts it introduced, and examples of the data collected by the company.

“This nationally prominent group of researchers has once again demonstrated that employers can bend the cost curve and improve outcomes, too,” says Editor-in-Chief David B. Nash, MD, MBA, Dean and Dr. Raymond C. and Doris N. Grandon Professor, Jefferson School of Population Health, Philadelphia, PA.

Source

Employers’ Role in Cancer Prevention and Treatment – Developing Success Metrics for Use by the CEO Roundtable on Cancer

Rachel Henke, Ron Z. Goetzel, Janice McHugh, Deborah Gorhan, Malinda Reynolds, Jaclyn Davenport, Kate Rasmussen, and Fikry Isaac. Population Health Management. -Not available-, ahead of print. doi:10.1089/pop.2012.0090. Online Ahead of Print: May 14, 2013

Mary Ann Liebert, Inc./Genetic Engineering News